These are the posts from the How we think section that have been tagged with Treatment.
To see all tags used in our posts, click here.
| 20th July 2017
Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.
| 19th May 2017
Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.
| 29th March 2017
Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.
| 23rd March 2017
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.
| 8th February 2017
When we talk about customers as experts in healthcare, what we’re really talking about are clinicians. Experts in diagnosis, treatment and clinical care (HCPs) and experts as those who experience the medical condition in their own personal context (patients). Head of Customer Experience Elisa del Galdo talks through how the evolution of the relationship between HCPs and patients is changing the role of the expert in healthcare.
| 9th January 2017
In the 2017 trends edition of Perspective magazine, we explore how advances in technology are influencing the future of the expert-patient relationship and the role healthcare businesses can take in supporting and enhancing these interactions at the point of need.
| 12th December 2016
The last decade has seen the rapid growth of biologics in the pharma market, making them a key sector to watch. With their growing popularity, it’s important to understand the opportunities and threats they present. Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.
| 16th November 2016
Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for patients.
| 19th September 2016
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.